Novo counters compounders with direct access channel for Wegovy, price cut for self-paying patients

Novo Nordisk is taking a page out of Eli Lilly’s playbook as the two GLP-1 drugmakers work to fend off compounding pharmacies that have been producing cheaper versions of their popular obesity products.